Loading stock data…
$10.12-0.15 (-1.46%)
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
MiNK Therapeutics, Inc. in the Healthcare sector is trading at $10.12 with a market capitalization of $56M. Wall Street consensus targets $39.00 (2 analysts), implying a +285.4% move over the next 12 months. The stock is currently near its 52-week low of $8.48, remaining 11.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.22M↓ | -$2.88M↑ | -$3.28M↓ | -$2.99M↑ | -$3.69M |
| Net Income | -$3.13M↓ | -$2.74M↓ | -$2.60M↑ | -$2.89M↑ | -$4.24M |
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and othe...